What changed today in Metabolic: 4 trial updates, 2 new studies

Why this matters

GLP-1 and obesity-medicine developments can change access, supply, clinical evidence and patient conversations for clinics, pharmacies and prescribers.

What changed

1. New trial registered: SEMA-T1D-BODY (Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.)[1]
2. New research in Endocrinology and metabolism (Seoul, Korea): “Transient Adipose Inflammatory Remodeling during High-Dose Semaglutide-Induced Weight Loss and Regain”.[2]
3. New research in Obesity reviews : an official journal of the International Association for the Study of Obesity: “GLP-1 Receptor Agonists and Cancer Risk in Obesity Treatment”.[3]
4. New trial registered: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With…[4]
5. New trial registered: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With…[5]
6. Trial status changed to “Completed”: INFLAM MOTION (A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and…)[6]

Who this affects

• Weight-management clinics
• Med spas
• Pharmacists
• Prescribers
• Medical directors
• Practice owners & operators

What to watch next

No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.

Source file

1. [1]
   New trial registered: SEMA-T1D-BODY (Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.) (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Oct 22, 2026

2. [2]
   Transient Adipose Inflammatory Remodeling during High-Dose Semaglutide-Induced Weight Loss and Regain (opens the source in a new tab)

   Peer reviewedEndocrinology and metabolism (Seoul, Korea)Oct 21, 2026

3. [3]
   GLP-1 Receptor Agonists and Cancer Risk in Obesity Treatment (opens the source in a new tab)

   Peer reviewedObesity reviews : an official journal of the International Association for the Study of ObesityOct 20, 2026

4. [4]
   New trial registered: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With… (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Oct 22, 2026

5. [5]
   New trial registered: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With… (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Oct 22, 2026

6. [6]
   Trial status changed to “Completed”: INFLAM MOTION (A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and…) (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Oct 22, 2026

Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.